ADMdx Logo


Peer-reviewed Journal Articles 

Shuping JL, Matthews DC, Adamczuk K, Scott D, Rowe CC, Kreisl WC, Johnson SC, Lukic AS, Johnson KA, Rosa-Neto P, Andrews RD, Van Laere K, Cordes L, Ward L, Wilde CL, Barakos J, Purcell DD, Devanand DP, Stern Y, Luchsinger JA, Sur C, Price JC, Brickman AM, Klunk WE, Boxer AL, Mathotaarachchi SS, Lao PJ, Evelhoch JL. Development, initial validation, and application of a visual read method for [18F]MK-6240 tau PET. Alzheimers Dement (N Y). 2023 Feb 12;9(1):e12372. doi: 10.1002/trc2.12372. ​ 

Smith AM, Obuchowski NA, Foster NL, Klein G, Mozley PD, Lammertsma AA, Wahl RL, Sunderland JJ, Vanderheyden JL, Benzinger TLS, Kinahan PE, Wong DF, Perlman ES, Minoshima S, Matthews D. The RSNA QIBA Profile for Amyloid PET as an Imaging Biomarker for Cerebral Amyloid Quantification. J Nucl Med. 2023 Feb;64(2):294-303. doi: 10.2967/jnumed.122.264031. ​ 

Konkel B, Macdonald J, Lafata K, Zaki IH, Bozdogan E, Chaudhry M, Wang Y, Janas G, Wiggins WF, Bashir MR. “Systematic Analysis of Common Factors Impacting Deep Learning Model Generalizability in Liver Segmentation.” Radiology: Artificial Intelligence, February 22, 2023.​ 

Matthews DC, Lukic AS, Andrews RD, Wernick MN, Strother SC, Schmidt ME; Alzheimer's Disease Neuroimaging Initiative. Measurement of neurodegeneration using a multivariate early frame amyloid PET classifier. Alzheimers Dement (N Y). 2022 Jul 8;8(1):e12325. doi: 10.1002/trc2.12325. ​ 

Raikes AC, Hernandez GD, Matthews DC, Lukic AS, Law M, Shi Y, Schneider LS, Brinton RD. Exploratory imaging outcomes of a phase 1b/2a clinical trial of allopregnanolone as a regenerative therapeutic for Alzheimer's disease: Structural effects and functional connectivity outcomes. Alzheimers Dement (N Y). 2022 Mar 14;8(1):e12258. doi: 10.1002/trc2.12258.​ 

Matthews DC, Mao X, Dowd K, Tsakanikas D, Jiang CS, Meuser C, Andrews RD, Lukic AS, Lee J, Hampilos N, Shafiian N, Sano M, David Mozley P, Fillit H, McEwen BS, Shungu DC, Pereira AC. Riluzole, a glutamate modulator, slows cerebral glucose metabolism decline in patients with Alzheimer's disease. Brain. 2021 Dec 31;144(12):3742-3755. doi: 10.1093/brain/awab222.​ 

Friedman LG, McKeehan N, Hara Y, Cummings JL, Matthews DC, Zhu J, Mohs RC, Wang D, Hendrix SB, Quintana M, Schneider LS, Grundman M, Dickson SP, Feldman HH, Jaeger J, Finger EC, Ryan JM, Niehoff D, Dickinson SL, Markowitz JT, Owen M, Travaglia A, Fillit HM. Value-Generating Exploratory Trials in Neurodegenerative Dementias. Neurology. 2021 May 18;96(20):944-954. doi: 10.1212/WNL.0000000000011774.​ 

Matthews DC, Ritter A, Thomas RG, Andrews RD, Lukic AS, Revta C, Kinney JW, Tousi B, Leverenz JB, Fillit H, Zhong K, Feldman HH, Cummings J. Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia. Alzheimers Dement (N Y). 2021 Feb 14;7(1):e12106. doi: 10.1002/trc2.12106.​ 

Obuchowski NA, Mozley PD, Matthews D, Buckler A, Bullen J, Jackson E. Statistical Considerations for Planning Clinical Trials with Quantitative Imaging Biomarkers.J Natl Cancer Inst. 2019 Jan 1;111(1):19-26. doi: 10.1093/jnci/djy194. ​ 

Rafii MS, Donohue MC, Matthews DC, Muranevici G, Ness S, O'Bryant SE, Rissman RA. Plasma Neurofilament Light and Alzheimer's Disease Biomarkers in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI). J Alzheimers Dis. 2019;70(1):131-138. doi: 10.3233/JAD-190322. ​ 

Walters MJ, Sterling J, Quinn C, Ganzer C, Osorio RS, Andrews RD, Matthews DC, Vallabhajosula S, de Leon MJ, Isaacson RS, Mosconi L. Associations of lifestyle and vascular risk factors with Alzheimer's brain biomarker changes during middle age: a 3-year longitudinal study in the broader New York City area. BMJ Open. 2018 Nov 25;8(11):e023664. doi: 10.1136/bmjopen-2018-023664. ​ 

Matthews DC, Lerman H, Lukic A, Andrews RD, Mirelman A, Wernick MN, Giladi N, Strother SC, Evans KC, Cedarbaum JM, Even-Sapir E. FDG PET Parkinson's disease-related pattern as a biomarker for clinical trials in early stage disease. Neuroimage Clin. 2018 Aug 10;20:572-579. doi: 10.1016/j.nicl.2018.08.006.​ 

Berti V, Walters M, Sterling J, Quinn CG, Logue M, Andrews R, Matthews DC, Osorio RS, Pupi A, Vallabhajosula S, Isaacson RS, de Leon MJ, Mosconi L. Mediterranean diet and 3-year Alzheimer brain biomarker changes in middle-aged adults. Neurology. 2018 May 15;90(20):e1789-e1798. doi: 10.1212/WNL.0000000000005527. ​ 

Mosconi L, Walters M, Sterling J, Quinn C, McHugh P, Andrews RD, Matthews DC, Ganzer C, Osorio RS, Isaacson RS, De Leon MJ, Convit A. Lifestyle and vascular risk effects on MRI-based biomarkers of Alzheimer's disease: a cross-sectional study of middle-aged adults from the broader New York City area. BMJ Open. 2018 Mar 23;8(3):e019362. doi: 10.1136/bmjopen-2017-019362.​ 

Rafii MS, Lukic AS, Andrews RD, Brewer J, Rissman RA, Strother SC, Wernick MN, Pennington C, Mobley WC, Ness S, Matthews DC; Down Syndrome Biomarker Initiative and the Alzheimer’s Disease Neuroimaging Initiative. PET Imaging of Tau Pathology and Relationship to Amyloid, Longitudinal MRI, and Cognitive Change in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI). J Alzheimers Dis. 2017;60(2):439-450. doi: 10.3233/JAD-170390. ​ 

Matthews DC, Lukic AS, Andrews RD, Marendic B, Brewer J, Rissman RA, Mosconi L, Strother SC, Wernick MN, Mobley WC, Ness S, Schmidt ME, Rafii MS. Dissociation of Down syndrome and Alzheimer's disease effects with imaging. Alzheimers Dement (N Y). 2016 Jun;2(2):69-81. doi: 10.1016/j.trci.2016.02.004.​ 

Schmidt ME, Chiao P, Klein G, Matthews D, Thurfjell L, Cole PE, Margolin R, Landau S, Foster NL, Mason NS, De Santi S, Suhy J, Koeppe RA, Jagust W; Alzheimer's Disease Neuroimaging Initiative. The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data. Alzheimers Dement. 2015 Sep;11(9):1050-68. doi: 10.1016/j.jalz.2014.09.004. ​ 

Matthews DC, Davies M, Murray J, Williams S, Tsui WH, Li Y, Andrews RD, Lukic A, McHugh P, Vallabhajosula S, de Leon MJ, Mosconi L. Physical Activity, Mediterranean Diet and Biomarkers-Assessed Risk of Alzheimer's: A Multi-Modality Brain Imaging Study. Adv J Mol Imaging. 2014 Oct;4(4):43-57. doi: 10.4236/ami.2014.44006.  ​ 

Mosconi L, Andrews RD, Matthews DC. Comparing brain amyloid deposition, glucose metabolism, and atrophy in mild cognitive impairment with and without a family history of dementia. J Alzheimers Dis. 2013;35(3):509-24. doi: 10.3233/JAD-121867. 

Yourganov G, Chen X, Lukic AS, Grady CL, Small SL, Wernick MN, Strother SC. Dimensionality estimation for optimal detection of functional networks in BOLD fMRI data. Neuroimage. 2011; 56(2):531-43.​ 

Strother, S., Oder, A., Spring, R., Grady, C. (2010). The NPAIRS Computational Statistics Framework for Data Analysis in Neuroimaging. In: Lechevallier, Y., Saporta, G. (eds) Proceedings of COMPSTAT'2010. Physica-Verlag HD. 

Schmidt ME, Andrews RD, van der Ark P et al. Dose-dependent effects of the CRF(1) receptor antagonist R317573 on regional brain activity in healthy male subjects. Psychopharmacology (Berl) 2010; 208:109-119.​ 

Lukic AS, Wernick MN, Tzikas DG, Chen X, Likas A, Galatsanos NP, Yang Y, Zhao F, Strother SC. Bayesian kernel methods for analysis of functional neuroimages. IEEE Trans Med Imaging. 2007 Dec;26(12):1613-24.​ 

Lukic AS, Wernick MN, Yang Y, Hansen LK, Arfanakis K, Strother SC. Effect of spatial alignment transformations in PCA and ICA of functional neuroimages. IEEE Trans Med Imaging. 2007 Aug;26(8):1058-68.​  

Book Chapters 

Matthews, D., & Schmidt, M. (2022). Brain Imaging for Alzheimer’s Disease Clinical Trials. In J. Cummings, J. Kinney, & H. Fillit (Eds.), Alzheimer's Disease Drug Development: Research and Development Ecosystem (pp. 375-394). Cambridge: Cambridge University Press. doi:10.1017/9781108975759.034​ 

Schmidt ME, Matthews D, Andrews R, Mosconi L. Positron Emission Tomography in Alzheimer Disease. Chapter 5, Translational Neuroimaging, Tools for CNS Drug Discovery, Development and Treatment. McArthur RA, ed., Academic Press, 2013; 131-174.​ 

Schmidt ME, Matthews DC, Andrews RA, Mosconi L. PET imaging in Alzheimer’s Disease. Book chapter in Brain imaging: Translational tools for CNS drug discovery, development, and treatment. McArthur R, ed. Elsevier, 2012.​ 

Miles N. Wernick and John N. Aarsvold, Emission Tomography: The Fundamentals of PET and SPECT, Elsevier 2004.​ 

ADMdx Logo
©2023. CorInsights® MRI is a registered trademark of AMDdx, 555 Skokie Blvd, Suite 500, Northbrook, IL, 60062, USA.